Avastin regaining foothold
We reiterate our outperform rating on Roche, after it announced today positive data from the ML18147 study exploring Avastin as a treatment through multiple lines in colorectal cancer patients. Avastin extended overall survival and the safety profile was consistent with that observed in previous studies. The positive data gives teeth to Avastin to further significantly increase its penetration in the colorectal cancer space. The detailed data will be presented at an upcoming conference. We expect incremental sales of $1b by virtue of this study.
The ML18147 study was conducted based on evidence from the data from BRiTE registry which was indicative of potential benefit of continuing treatment with Avastin in patients who have progressed on first line avastin therapy. In the Brite Registry, of the 1445 patients which were studied post progression, those with avastin therapy, lived the longest (19.2 mo – avastin therapy post progression, vs 9.5 m – chemotherapy post progression vs 3.6 m – no therapy post progression
The ML18147 study was conducted based on evidence from the data from BRiTE registry which was indicative of potential benefit of continuing treatment with Avastin in patients who have progressed on first line avastin therapy. In the Brite Registry, of the 1445 patients which were studied post progression, those with avastin therapy, lived the longest (19.2 mo – avastin therapy post progression, vs 9.5 m – chemotherapy post progression vs 3.6 m – no therapy post progression
COMPANIES MENTIONED
ROCHE, SANOFI, REGENERON
ROCHE, SANOFI, REGENERON
